Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gerritsen

Showing results (141-150 of 224) with videos related to

Pageof 23
Sort By:
Journal for Immunotherapy of Cancer|July 22, 2015
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumabSaskia Jam Santegoets, Anita Gm Stam, Sinéad M Lougheed, et al.
British Journal of Cancer|February 25, 2022
Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancerPeter H J Slootbeek, Iris S H Kloots, Minke Smits, et al.
Blood|November 15, 1995
The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of plateletsM W Dercksen, I S Weimar, D J Richel, et al.
Vaccine|May 15, 2003
CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activationJoana G Brandão, Rik J Scheper, Sinéad M Lougheed, et al.
Cancers|September 28, 2021
Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial CancerSandra van Wilpe, Victoria Wosika, Laura Ciarloni, et al.
Blood|August 12, 2011
Blood platelets contain tumor-derived RNA biomarkersR Jonas A Nilsson, Leonora Balaj, Esther Hulleman, et al.
British Journal of Cancer|December 16, 2021
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancerPeter H J Slootbeek, Iris S H Kloots, Minke Smits, et al.
British Journal of Cancer|June 1, 2006
Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatinH C A Graat, M A Witlox, F H E Schagen, et al.
Molecular Cancer Therapeutics|August 27, 2003
Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2Dinja Oosterhoff, M Adhiambo Witlox, Victor W van Beusechem, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancerMaarten J van der Doelen, Pedro Isaacsson Velho, Peter H J Slootbeek, et al.
Pageof 23

Showing results (141-150 of 224) with videos related to

Sort By:
Pageof 23
Journal for Immunotherapy of Cancer|July 22, 2015
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumabSaskia Jam Santegoets, Anita Gm Stam, Sinéad M Lougheed, et al.
British Journal of Cancer|February 25, 2022
Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancerPeter H J Slootbeek, Iris S H Kloots, Minke Smits, et al.
Blood|November 15, 1995
The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of plateletsM W Dercksen, I S Weimar, D J Richel, et al.
Vaccine|May 15, 2003
CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activationJoana G Brandão, Rik J Scheper, Sinéad M Lougheed, et al.
Cancers|September 28, 2021
Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial CancerSandra van Wilpe, Victoria Wosika, Laura Ciarloni, et al.
Blood|August 12, 2011
Blood platelets contain tumor-derived RNA biomarkersR Jonas A Nilsson, Leonora Balaj, Esther Hulleman, et al.
British Journal of Cancer|December 16, 2021
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancerPeter H J Slootbeek, Iris S H Kloots, Minke Smits, et al.
British Journal of Cancer|June 1, 2006
Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatinH C A Graat, M A Witlox, F H E Schagen, et al.
Molecular Cancer Therapeutics|August 27, 2003
Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2Dinja Oosterhoff, M Adhiambo Witlox, Victor W van Beusechem, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancerMaarten J van der Doelen, Pedro Isaacsson Velho, Peter H J Slootbeek, et al.
Pageof 23